Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (AU:RMD)
ASX:RMD
Earnings Data
Report Date
Apr 30, 2026After Close (Confirmed)
Period Ending
2026 (Q3)Consensus EPS Forecast
0.41Last Year’s EPS
0.34Same Quarter Last Year
Strong Buy
Based on 9 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call communicated broad financial and operational strength: top‑line growth (11% headline, 9% cc), solid device and mask performance, margin expansion, double‑digit EPS growth, strong cash generation and active capital returns. Management highlighted multiple growth engines—new product launches (fabric masks), AI (Comfort Match), supply‑chain margin initiatives, software tuck‑ins and a favorable demand tailwind from patients associated with GLP‑1 therapies. Near‑term challenges were limited: RCS vertical softness in senior living/long‑term care, a modest restructuring charge, higher SG&A (partly from acquisitions and marketing), and a higher effective tax rate. Overall, positives materially outweighed negatives across key metrics and strategic initiatives.Company Guidance
RCS & Software Progress and Strategic M&A
Residential care software (RCS) revenue rose ~5% (cc); management progressing portfolio management work with a target to return RCS to sustainable high single‑digit growth and double‑digit operating profit growth by FY27. Recent tuck‑in M&A (VirtuOx, EctoSense, Somnaware) expanding diagnostic and virtual testing capabilities.
Real‑World Evidence & Clinical Engagement
Claims analysis of ~1.95 million patients: patients with both GLP‑1 and CPAP scripts are 10%–11% more likely to start CPAP; +3% likelihood of resupply at 1 year and ~6% (6.2%) likelihood at 3 years, indicating a durable tailwind. CME programs completed nearly 60,000 times (50% increase from prior quarter) and 77% of completing providers intend to change clinical practice.
Revenue Growth
Group revenue of $1.42 billion, an 11% headline increase and 9% growth on a constant currency basis versus prior-year quarter.
Device and Mask Performance
Global device sales grew 11% (constant currency). Masks, accessories and other revenue grew 14% globally (constant currency); U.S. masks/accessories up ~16% and Europe/Asia/ROW masks/accessories up ~8% (cc).
Gross Margin Expansion and Supply‑Chain Productivity
Reported gross margin was 32.3% for the quarter. Management highlighted supply‑chain improvements that contributed meaningfully to margin expansion (management cited a 310 bps YoY benefit from supply chain initiatives; company-wide gross margin improvement reported as +110 bps YoY and +30 bps sequentially). Guidance for FY26 gross margin range reiterated at ~62%–63% (non‑GAAP context).
Operating Profit and EPS Growth
Operating profit increased 19% year‑over‑year; operating margin improved to 36.3% of revenue (from 34.0% prior year). GAAP diluted EPS grew 16% and net income increased ~15%.
Cash Generation and Balance Sheet Strength
Operating cash flow of $340 million for the quarter; cash balance $1.4 billion, gross debt $664 million, net cash ~$753 million, and ~$1.5 billion available under revolver.
Shareholder Returns
Returned $263 million to shareholders via dividends and $175 million of share repurchases in the quarter; board declared a $0.60/share quarterly dividend and repurchases targeted at >$600 million for FY26.
Product and R&D Momentum
Launched new fabric full‑face masks (F30i Comfort and F30i Clear) with positive early feedback and expected adoption; continued investment in cloud‑connected devices and software (R&D ~6%–7% of revenue guidance).
AI and Digital Innovation
Limited beta of Comfort Match (AI‑enabled comfort setting recommender within myAir), noted as the company's first FDA‑cleared AI‑enabled medical device; expected to improve therapy initiation and long‑term adherence.
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (AU:RMD) Earnings, Revenues Date & History
AU:RMD Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
AU:RMD Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Jan 29, 2026 | AU$36.32 | AU$37.46 | +3.13% |
Oct 30, 2025 | AU$38.71 | AU$39.35 | +1.65% |
Jul 31, 2025 | AU$42.17 | AU$42.59 | +1.02% |
Apr 23, 2025 | AU$32.95 | AU$35.76 | +8.51% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (AU:RMD) report earnings?
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (AU:RMD) is schdueled to report earning on Apr 30, 2026, After Close (Confirmed).
What is Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (AU:RMD) earnings time?
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (AU:RMD) earnings time is at Apr 30, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock?
The P/E ratio of Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh is N/A.
What is AU:RMD EPS forecast?
AU:RMD EPS forecast for the fiscal quarter 2026 (Q3) is 0.41.